title: Intensive cardiac management in patients with trisomy 13 or trisomy 18.
abstract: Intensive cardiac management such as pharmacological intervention for ductal patency (indomethacin and/or mefenamic acid for closure and prostaglandin E1 for maintenance) and palliative or corrective surgery is a standard treatment for congenital heart defects. However, whether it would be a treatment option for children with trisomy 13 or trisomy 18 syndrome is controversial because the efficacy on survival in patients with these trisomies has not been evaluated. We retrospectively reviewed 31 consecutive neonates with trisomy 13 or trisomy 18 admitted to our neonatal ward within 6 hr of birth between 2000 and 2005. The institutional management policies differed during three distinct periods. In the first period, both pharmacological ductal intervention and cardiac surgery were withheld. In the second, pharmacological ductal intervention was offered as an option, but cardiac surgery was withheld. Both strategies were available during the third period. The median survival times of 13, 9, and 9 neonates from the first, second, and third periods were 7, 24, and 243 days, respectively. Univariate and multivariate analyses confirmed that the patients in the third period survived significantly longer than the others. Intensive cardiac management consisting of pharmacological intervention for ductal patency and cardiac surgery was demonstrated to improve survival in patients with trisomy 13 or trisomy 18 in this series. Therefore, we suggest that this approach is a treatment option for cardiac lesions associated with these trisomies. These data are helpful for clinicians and families to consider in the optimal treatment of patients with these trisomies.
authors.affiliation: Department of Cardiovascular Surgery, Japanese Red Cross Medical Center, Tokyo, Japan. yukihirokaneko@hotmail.com
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Kaneko
authors.forename: Jotaro
authors.initials: J
authors.lastname: Kobayashi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yoda
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kanetaka
authors.forename: Yayohi
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Daiichi
authors.initials: D
authors.lastname: Endo
authors.forename: Keiji
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Hajime
authors.initials: H
authors.lastname: Sato
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kawakami
mesh_terms: D006348:Cardiac Surgical Procedures; D002882:Chromosomes, Human, Pair 13; D002887:Chromosomes, Human, Pair 18; D015331:Cohort Studies; D006330:Heart Defects, Congenital / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D007564:Japan; D014314:Trisomy; D028761:Withholding Treatment